Teva Reaches License Deal With Prestige Biopharma for Cancer Medication in Europe

Dow Jones

Oct 21

By Dean Seal

A subsidiary of Teva Pharmaceuticals Industries has reached a license agreement with Prestige Biopharma for the commercialization of the cancer medicine Tuznue across most European markets.

Teva Pharmaceuticals International said Monday that Prestige received marketing authorization last year from the European Commission for Tuznue, a biosimilar to Herceptin approved for the treatment of breast cancer and metastatic gastric cancer.

Under their license and supply deal, Teva has secured the rights to market and distribute Tuznue in a majority of European markets. Prestige will be responsible for production and supply.

"Teva's extensive market reach will drive the successful launch of Tuznue while accelerating the development of our broader biosimilar pipeline," Prestige CEO Lisa Park said.

Write to Dean Seal at dean.seal@wsj.com

(END) Dow Jones Newswires

October 20, 2025 16:48 ET (20:48 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2577889599"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2577889599\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2577889599?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-21 04:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2577889599","market":"us","top_or_hot":-1,"title":"Teva Reaches License Deal With Prestige Biopharma for Cancer Medication in Europe","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Dean Seal \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  A subsidiary of <a href=\"https://laohu8.com/S/TEVA\">Teva</a> Pharmaceuticals Industries has reached a license agreement with Prestige Biopharma for the commercialization of the cancer medicine Tuznue across most European markets. \n</p>\n<p>\n  Teva Pharmaceuticals International said Monday that Prestige received marketing authorization last year from the European Commission for Tuznue, a biosimilar to Herceptin approved for the treatment of breast cancer and metastatic gastric cancer. \n</p>\n<p>\n  Under their license and supply deal, Teva has secured the rights to market and distribute Tuznue in a majority of European markets. Prestige will be responsible for production and supply. \n</p>\n<p>\n  \"Teva's extensive market reach will drive the successful launch of Tuznue while accelerating the development of our broader biosimilar pipeline,\" Prestige CEO Lisa Park said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Dean Seal at dean.seal@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 20, 2025 16:48 ET (20:48 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Teva Reaches License Deal With Prestige Biopharma for Cancer Medication in Europe</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTeva Reaches License Deal With Prestige Biopharma for Cancer Medication in Europe\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-10-21 04:48</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Dean Seal \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  A subsidiary of <a href=\"https://laohu8.com/S/TEVA\">Teva</a> Pharmaceuticals Industries has reached a license agreement with Prestige Biopharma for the commercialization of the cancer medicine Tuznue across most European markets. \n</p>\n<p>\n  Teva Pharmaceuticals International said Monday that Prestige received marketing authorization last year from the European Commission for Tuznue, a biosimilar to Herceptin approved for the treatment of breast cancer and metastatic gastric cancer. \n</p>\n<p>\n  Under their license and supply deal, Teva has secured the rights to market and distribute Tuznue in a majority of European markets. Prestige will be responsible for production and supply. \n</p>\n<p>\n  \"Teva's extensive market reach will drive the successful launch of Tuznue while accelerating the development of our broader biosimilar pipeline,\" Prestige CEO Lisa Park said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Dean Seal at dean.seal@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 20, 2025 16:48 ET (20:48 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4559","symbol_name":"巴菲特持仓","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2577889599","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2577889599","pubTimestamp":1760993280,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"A subsidiary of Teva Pharmaceuticals Industries has reached a license agreement with Prestige Biopharma for the commercialization of the cancer medicine Tuznue across most European markets.Teva Pharmaceuticals International said Monday that Prestige received marketing authorization last year from the European Commission for Tuznue, a biosimilar to Herceptin approved for the treatment of breast cancer and metastatic gastric cancer.Under their license and supply deal, Teva has secured the rights to market and distribute Tuznue in a majority of European markets. Prestige will be responsible for production and supply.\"Teva's extensive market reach will drive the successful launch of Tuznue while accelerating the development of our broader biosimilar pipeline,\" Prestige CEO Lisa Park said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4559":"巴菲特持仓","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","BK4596":"哈里斯概念","BK4007":"制药","BK4584":"避孕概念","PBH":"普雷斯蒂奇","TEVA":"梯瓦制药","BK4566":"资本集团","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4557":"大麻股"},"translate_title":"梯瓦与Prestige Biopharma在欧洲达成癌症药物许可协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TEVA":0.9,"PBH":1.5},"content_text":"By Dean Seal \n\n\n \n\n\n  A subsidiary of Teva Pharmaceuticals Industries has reached a license agreement with Prestige Biopharma for the commercialization of the cancer medicine Tuznue across most European markets. \n\n\n  Teva Pharmaceuticals International said Monday that Prestige received marketing authorization last year from the European Commission for Tuznue, a biosimilar to Herceptin approved for the treatment of breast cancer and metastatic gastric cancer. \n\n\n  Under their license and supply deal, Teva has secured the rights to market and distribute Tuznue in a majority of European markets. Prestige will be responsible for production and supply. \n\n\n  \"Teva's extensive market reach will drive the successful launch of Tuznue while accelerating the development of our broader biosimilar pipeline,\" Prestige CEO Lisa Park said. \n\n\n \n\n\n  Write to Dean Seal at dean.seal@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 20, 2025 16:48 ET (20:48 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}